0001213900-24-041278.txt : 20240509 0001213900-24-041278.hdr.sgml : 20240509 20240509160135 ACCESSION NUMBER: 0001213900-24-041278 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240503 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevai Labs Inc. CENTRAL INDEX KEY: 0001840563 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851399981 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41875 FILM NUMBER: 24930293 BUSINESS ADDRESS: STREET 1: 120 NEWPORT CENTER DRIVE STREET 2: STE 250 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: 18667944940 MAIL ADDRESS: STREET 1: 120 NEWPORT CENTER DRIVE STREET 2: STE 250 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 FORMER COMPANY: FORMER CONFORMED NAME: Reactive Medical Labs Inc. DATE OF NAME CHANGE: 20210114 8-K 1 ea0205583-8k_elevai.htm CURRENT REPORT
false 0001840563 0001840563 2024-05-03 2024-05-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 3, 2024 

 

Elevai Labs Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-41875   85-1399981

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification No.)

 

c/o 120 Newport Center Drive, Ste. 250

Newport Beach, CA

  92660
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 866-794-4940

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   ELAB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On May 3, 2024, the Board of Directors (the “Board”) of Elevai Labs Inc. (the “Company”) approved the Company entering into a one-year consulting agreement (the “Agreement”) with Santorio Biomedical, LLC (the “Consultant”) for the services of Mr. Deniel Mero, Director of Santorio Biomedical, LLC, whereby the Consultant will cause Mr. Mero to perform his services as outlined in Exhibit A to the Agreement and Consultant will be compensated on behalf of Mr. Mero by the Company in connection with his performance of such services. The Consultant will cause Mr. Mero, as an independently contracted consultant to primarily provide services to the Company’s wholly owned subsidiary Elevai Biosciences Inc., an Elevai Labs company which include but are not limited to, (i) discover, assess, and introduce biotechnology opportunities to the Company; (ii) advise the Board regarding certain strategic matters, including development of biotechnology pipeline assets, recruiting a contract research organization (CRO), assisting in efforts to recruit potential directors and team members to build the biotechnology division and forming a scientific advisory board; and (iii) to perform services for subsidiaries of the Company as may be necessary.

 

The Consultant will receive a $180,000 fee per year payable in monthly installments. In addition, the Consultant was granted 2,450,000 shares of restricted common stock (the “Shares”) payable in four installments over the course of ten months, which Mr. Mero will be deemed to beneficially own indirectly. Within one year after the final and fourth grant of the Shares, the Company has agreed to register the Shares under a registration statement to be filed with the United States Securities and Exchange Commission.

 

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated in its entirety herein by reference.

  

Item 9.01 Financial Statements and Exhibits. 

 

(d) Exhibits. 

 

The following exhibits are being filed herewith: 

 

Exhibit No.   Description
10.1   Consulting Agreement with Santorio Biomedical, LLC  
104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 9, 2024

 

Elevai Labs, Inc.  
     
By: /s/ Jordan R. Plews  
Name:  Jordan R. Plews  
Title: Chief Executive Officer, President and Director  

 

 

2

 

 EX-10.1 2 ea020558301ex10-1_elevai.htm CONSULTING AGREEMENT WITH SANTORIO BIOMEDICAL, LLC

Exhibit 10.1

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “Agreement”), effective as of May 3, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation (“Company”), and Santorio Biomedical, LLC, a Delaware limited liability company (“Consultant”).

 

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows.

 

1. Consulting Relationship. During the term of this Agreement, Consultant will perform for Company the consulting services as described on Exhibit A (the “Services”). Consultant shall perform the Services in a diligent and professional matter, and in compliance with all applicable laws and regulations. Without limiting the foregoing, Company acknowledges that the relationship with Consultant is not exclusive, and that Consultant may perform services for other parties that are the same or similar to the Services provided for Company hereunder, provided that Consultant at all times abides by the Confidentiality Agreement (as defined below) and the terms and provisions of this Agreement intended to survive the expiration or termination thereof.

 

2. Fees. As consideration for the Services performed by Consultant and other obligations, Company shall pay Consultant the amounts specified in Exhibit B at the times specified therein.

 

3. Expenses. Consultant will be responsible for all expenses incurred while performing the Services unless Consultant receives the prior written approval of the Company to reimburse a particular expense. Without limiting the right of Company to deny approval, as a condition to receipt of reimbursement, Consultant shall be required to submit to Company reasonable evidence that the amount involved was both reasonable and necessary to the Services provided under this Agreement.

 

4. Term and Termination.

 

(a) Subject to section 4(b), this Agreement shall commence on the Effective Date and continue in force until May 3, 2025 (the “Expiration Date”), unless earlier terminated in accordance with this Section 4 or extended by mutual written agreement of both parties (as the case may be, the “Term”).

 

(b) Either party may terminate this Agreement prior to the Expiration Date for any or no reason, by providing at least thirty (30) days prior written notice to the other party.

 

(c) If (i) Company breaches any of its obligations pursuant to this Agreement or (ii) Consultant breaches any of its obligations pursuant to this Agreement including, but not limited to, Consultant’s obligations under the Confidential Information and Invention Assignment Agreement between Company and Consultant, the form of which is attached hereto as Exhibit C (the “Confidentiality Agreement”), then the non-breaching party may terminate this Agreement by providing written notice to the breaching party setting forth the basis for the termination. Termination for breach shall become effective upon the non-breaching party’s delivery of notice provided that the breaching party fails to cure within five (5) business days thereafter.

 

(d) If this Agreement is terminated for any or no reason, the Company shall nevertheless issue the Shares listed in Exhibit B as specified therein and use commercially reasonable efforts to register the Shares.

 

 

 

 

5. Independent Contractor. Consultant’s relationship with Company will be that of an independent contractor and not that of an employee or agent. Unless authorized by the Company in writing in advance, Consultant shall provide its own office space, equipment, and supplies necessary to perform the Services.

 

6. Provision of Services. Consultant is responsible for determining the method, details and means of performing the Services.

 

7. No Authority to Bind Company. Neither Consultant nor any of its personnel has the authority to enter into any contract that binds Company or creates any obligations on the part of Company.

 

8. No Benefits. Neither Consultant nor any of its personnel is eligible for any Company employee benefits. Further, to the extent Consultant or any of its personnel otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Consultant on behalf of itself and its personnel hereby expressly declines to participate in such Company employee benefits.

 

9. Taxes. Consultant shall have full responsibility for applicable withholding taxes for all compensation paid to Consultant under this Agreement, and for compliance with all applicable labor and employment requirements with respect to Consultant’s self- employment, franchise tax, worker’s compensation insurance coverage requirements and U.S. immigration visa requirements.

 

10. Confidential Information and Invention Assignment Agreement. Consultant shall sign, or has signed, the Confidentiality Agreement, which shall be effective as of the Effective Date. Consultant shall ensure that each of its personnel performing the Services on behalf of Consultant shall have entered into confidentiality agreement with Consultant obligating such personnel to abide by the provisions of this Agreement.

 

11. Representations and Warranties

 

(a) Consultant represents and warrants that: (i) Neither Consultant nor any of its personnel is under any pre-existing obligation in conflict or in any way inconsistent with the provisions of this Agreement; (ii) Consultant’s performance of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by Consultant in confidence or in trust prior to commencement of this Agreement. (iii) to Consultant’s knowledge, Consultant has all rights, licenses and permissions required for it to perform the Services and receive the compensation hereunder.

 

(b) Company represents and warrants that: (i) it has the full right, power, and authority to enter into this Agreement and to perform its obligations hereunder; and (ii) the execution of this Agreement by its representative whose signature is set forth at the end of this Agreement has been duly authorized by all necessary corporate action.

 

12. MUTUAL LIMITATION OF LIABILITY. IN NO EVENT WILL COMPANY OR CONSULTANT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH THIS AGREEMENT, EVEN IF COMPANY OR CONSULTANT HAS BEEN INFORMED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.

 

2

 

 

13. Indemnification.

 

(a) By Company. The Company shall defend, indemnify, and hold harmless the Consultant and its affiliates and their officers, directors, employees, agents, successors, and assigns (“Consultant Indemnitees”), to the fullest extent permitted by law, from and against all losses, liabilities, deficiencies, actions (including derivative shareholder actions), judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind (including reasonable attorneys’ fees) arising out of or resulting from the Company’s use or reliance on Consultant’s Services or advice or information provided by Consultant, except to the extent of any bad faith or intentional or willful misconduct of any Consultant Indemnitees. In no event shall the aggregate liability of the Company connection with any and all claims arising out of this Agreement exceed the aggregate amount of cash compensation paid by the Company to Consultant pursuant to this Agreement.

 

(b) By Consultant. Consultant shall indemnify, defend and hold harmless the Company and its affiliates and their officers, directors, employees, agents, successors, and assigns (“Company Indemnitees”) from and against all losses, liabilities, deficiencies, actions (including derivative shareholder actions), judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind (including reasonable attorneys’ fees) arising out of or resulting from any bad faith or intentional or willful misconduct of any Consultant Indemnitee, or any breach of or failure to comply with this Agreement on the part of any Company Indemnitee. In no event shall the aggregate liability of Consultant in connection with any and all claims arising out of this Agreement, the Services or any deliverables provided by Consultant exceed the aggregate amount of cash compensation paid by the Company to Consultant pursuant to this Agreement.

 

14. Miscellaneous.

 

(a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the principles of conflict of law provisions thereof. Any dispute or controversy arising under or in connection with this Agreement shalt be settled exclusively by arbitration in Orange County, California in accordance with the rules of the American Arbitration Association (“AAA”) then in effect. Arbitration will take place before a single experienced arbitrator licensed to practice law in California. Any judgment rendered by the arbitrator as above provided shall be final and binding on the parties hereto for all purposes and may be entered in any court having jurisdiction. In any arbitration pursuant to this Section 14(a), each party shall be responsible for the fees and expenses of its own attorney and witnesses, and the fees and expenses of the arbitrator shall be divided equally between Company and the Consultant. Consultant agrees that the cost provisions of this Section 14(a) are fair and not unconscionable.

 

(b) Entire Agreement; Other Agreements. This Agreement, together with the Confidentiality Agreement, sets forth the entire agreement and understanding of the parties relating to the subject matter herein and therein. For the avoidance of doubt, this Agreement supersedes all prior or contemporaneous discussions, understandings and agreements (original or amended), whether oral or written, between them relating to the subject matter hereof.

 

(c) Amendments and Waivers. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that provision as to that or any other instance.

 

3

 

 

(d) Successors and Assigns. Consultant may not assign, whether voluntarily or by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of Company. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the respective successors, assigns, heirs, executors, administrators and legal representatives of the parties.

 

(e) Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient when delivered personally, by overnight courier or sent by email, addressed to the party to be notified at such party’s address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at the most recent address set forth in Company’s books and records.

 

(f) Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.

 

(g) Construction. This Agreement is the result of negotiations between and has been reviewed by each of the parties and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of both parties, and no ambiguity shall be construed in favor of or against either party.

 

(h) Signatures. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which together shall constitute one and the same agreement. Signatures received by facsimile, PDF file or other electronic format (including DocuSign) shall be deemed to be original signatures.

 

[Signature Page Follows]

 

4

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement and made it effective as of the Effective Date.

 

 

 

COMPANY:

     
 

ELEVAI LABS INC.

     
  By: /s/ Graydon Bensler
  Name: Graydon Bensler
  Title: CFO and Director

  Address: 

120 Newport Center Drive, Newport Beach, CA 92660, USA

 

  CONSULTANT:
     
  SANTORIO BIOMEDICAL, LLC
     
  By: /s/ Deniel Mero
  Name: Deniel Mero
  Title: Director

  Address:  99 Wall St, Suite 1925, New York, NY, 10005

  Business Tax ID: 37-2118799

 

 

5

 

 

EXHIBIT A

 

DESCRIPTION OF SERVICES

 

(1)Discover, assess, and introduce biotechnology opportunities to the Company.

 

(2)Advise the Board of Directors regarding certain strategic matters, including development of biotechnology pipeline assets, recruiting a contract research organization (CRO), assisting in efforts to recruit potential directors and team members to build the biotechnology division and forming a scientific advisory board.

 

(3)Provide advice and support for investor relations and capital markets awareness by building marketing materials and generating a plan to circuit investment conferences with Company.

 

(4)Strategize with Company IP lawyers to compose a patent portfolio.

 

(5)The foregoing Services may be performed in the Consultant’s (or Consultant’s personnel) capacity as an officer of the Company, subject to terms and conditions to be agreed by the parties in writing.

 

6

 

 

EXHIBIT B

 

COMPENSATION

 

This Exhibit B sets forth the compensation to be paid in exchange for the performance of the Services specified in Exhibit A.

 

Consultant will be compensated with a monthly cash fee of $15,000 for Consultant’s fractional time of approximately 60%. In addition, the Company shall promptly (but no later than 5 business days from the issuance dates below (each an “Issuance Date”) take all required steps to issue shares of common stock of Elevai Labs Inc., par value $0.0001 per share (the “Shares”):

 

·Effective Date: 612,500 Shares

 

·August 1, 2024: 612,500 Shares

 

·November 1, 2024: 612,500 Shares

 

·February 2, 2025: 612,500 Shares

 

If this Agreement is terminated for any or no reason, Company shall issue the full number of Shares listed above immediately and use commercially reasonable efforts to register the Shares. For clarity, if this Agreement is terminated before the full 2,450,000 Shares have been issued to Consultant, Company will issue the full 2,450,000 Shares to Consultant immediately upon termination of Agreement; provided, however, that (notwithstanding the foregoing) Shares not previously issued or issuable by the Company hereunder shall no longer be issuable by the Company hereunder if, prior to the Issuance Date thereof as set forth above, the Consultant (or its personnel performing Services): (i) fundamentally or materially fails to perform the Services after being provided with written notice of such failure and a 30 day period to cure; (ii) stands convicted by a court of any fraud, theft, embezzlement or other criminal act of a similar nature; (iii) engages in an act of intentional and material dishonesty or fraud; or (iv) materially breaches of any material term of the Confidentiality Agreement.

 

Further Shares

 

Consultant agrees that it, together with its Affiliates, will in no event acquire or own any shares of common stock of Elevai Labs Inc., par value $0.0001 per share, other than the Shares issued to Consultant hereunder without the prior written consent of Company.

 

For purposes of the foregoing “Affiliate” means, with respect to Consultant, any other person or entity which directly or indirectly controls, is controlled by, or is under common control with, Consultant. For the purposes of this definition, a person or entity shall be regarded as in control of or common control with Consultant if it or Deniel Mero owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest such person or entity, or if Consultant or Deniel Mero directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other person or entity by any means whatsoever.

 

Registration Rights

 

The Company agrees that it will use its commercially reasonable efforts to file with the Securities and Exchange Commission (the “SEC”) (at Company’s sole cost and expense), within one year after the final issuance of Shares hereunder (the “One-Year Period”), a registration statement (the “Registration Statement”) registering the resale of such Shares issued to Consultant hereunder (“Registrable Securities”), and the Company shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof; provided, however, that: (i) if the Company shall during the One-Year Period file any registration statement for any other primary or secondary sale of shares of its common stock with the SEC, then such Registrable Securities shall be included therein (and such registration statement shall constitute the “Registration Statement” hereunder); and (ii) the Company’s obligations to include the Registrable Securities in the Registration Statement are contingent upon Consultant furnishing in writing to the Company such information regarding Consultant, the securities of Company held by Consultant and its affiliates and the intended method of disposition of the Registrable Securities as shall be reasonably requested by the Company to effect the registration of the Registrable Securities, and shall execute such documents in connection with such registration as the Company may reasonably request that are customary of a selling stockholder in similar situations, and provided that the Company shall be entitled to postpone and suspend the effectiveness or use of the Registration Statement during any customary blackout or similar period or as otherwise permitted by Consultant.

 

7

 

 

EXHIBIT C

 

CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT

 

 

 

 

8

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

 

 

COMPANY:

     
 

ELEVAI LABS INC.

     
  By: /s/ Graydon Bensler
    (Signature)
  Name: Graydon Bensler
  Title: CFO and Director

  Address: 

120 Newport Center Drive, Newport Beach, CA 92660 USA

 

  CONSULTANT:
     
 

Santorio Biomedical, LLC

     
  By: /s/ Deniel Mero
  Name: Deniel Mero
  Title: Director

  Address:  99 Wall St, Suite 1925, New York, NY, 10005

 

9

 

 

EXHIBIT A-1

 

LIST OF PRIOR INVENTIONS EXCLUDED UNDER SECTION 4(a)

 

 

10

 

 EX-101.SCH 3 elab-20240503.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 elab-20240503_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 elab-20240503_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 03, 2024
Entity File Number 001-41875
Entity Registrant Name Elevai Labs Inc.
Entity Central Index Key 0001840563
Entity Tax Identification Number 85-1399981
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One c/o 120 Newport Center Drive
Entity Address, Address Line Two Ste. 250
Entity Address, City or Town Newport Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92660
City Area Code 866
Local Phone Number 794-4940
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol ELAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elevaiskincare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0205583-8k_elevai.htm elab-20240503.xsd elab-20240503_lab.xml elab-20240503_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0205583-8k_elevai.htm": { "nsprefix": "ELAB", "nsuri": "http://elevaiskincare.com/20240503", "dts": { "inline": { "local": [ "ea0205583-8k_elevai.htm" ] }, "schema": { "local": [ "elab-20240503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "elab-20240503_lab.xml" ] }, "presentationLink": { "local": [ "elab-20240503_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://elevaiskincare.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0205583-8k_elevai.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0205583-8k_elevai.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://elevaiskincare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-24-041278-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-041278-xbrl.zip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end XML 17 ea0205583-8k_elevai_htm.xml IDEA: XBRL DOCUMENT 0001840563 2024-05-03 2024-05-03 iso4217:USD shares iso4217:USD shares false 0001840563 8-K 2024-05-03 Elevai Labs Inc. DE 001-41875 85-1399981 c/o 120 Newport Center Drive Ste. 250 Newport Beach CA 92660 866 794-4940 false false false false Common Stock, $0.0001 par value ELAB NASDAQ true false